References
- Taoka K, Kumano K, Nakamura F, et al. The effect of iron overload and chelation on erythroid differentiation. Int J Hematol. 2012;95:149–159.
- Shenoy N, Vallumsetia N, Rachmilewitz E, et al. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–881.
- Manduzio P. Deferasirox in a refractory anemia after other treatment options: case report and literature review. Clin Case Rep. 2015;3:361–367.
- Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012;97:1364–1371.
- Elli EM, Belotti A, Arolda A, et al. Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. Mediterr J Hematol Infect Dis. 2014;6:e2014042.
- Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol. 2008;120:70–74.
- Guariglia R, Martorelli MC, Villani O, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res. 2011;35:566–570.
- Richardson DR, Kalinowski DS, Lau S. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 2009;1790:702–717.
- Banerjee A, Mifsud NA, Bird R, et al. The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia. Br J Haematol. 2015;168:576–582.
- Messa E, Carturan S, Maffè C, et al. Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica. 2010;95:1308–1316.
- Kiessling MK, Klemke CD, Kaminski MM, et al. Inhibition of constitutively activated nuclear factor-KB induces reactive oxygen species- and iron-dependent cell death in cutaneous T-cell lymphoma. Cancer Res. 2009;69:2365–2374.
- Whittaker P, Seifried HE, San RHC, et al. Genotoxicity of iron chelators in L5178Y mouse lymphoma cells. Environ Mol Mutagen. 2001;38:347–356.
- Choi JG, Kim JL, Park J, et al. Effects of oral iron chelator deferasirox on human malignant lymphoma cells. Korean J Hematol. 2012;47:194–201.
- Vazana-Barad L, Granot G, Mor-Tzuntz R, et al. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma. Leuk Lymph. 2013;54:851–859.
- Lee D, Jang P, Chung N, et al. Deferasirox shows in vitro and in vivo antileukaemic effects on murine leukaemic cell lines regardless of iron status. Exp Haematol. 2013;41:539–546.